期刊
MEMBRANES
卷 13, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/membranes13020150
关键词
cholecystokinin; cholecystokinin receptor; G protein-coupled receptor; positive allosteric modulator; obesity
In an effort to develop a drug for obesity, researchers performed a high throughput screening of small molecules to find candidates that can enhance the action of CCK. The study focused on a specific scaffold of tetracyclic molecules and expanded it with commercially available analogs, eliminating off-target effects while retaining its activity as a positive allosteric modulator of CCK1R. These findings provide valuable insights for the future development of potential therapeutic candidates.
As part of an ongoing effort to develop a drug targeting the type 1 cholecystokinin receptor (CCK1R) to help prevent and/or treat obesity, we recently performed a high throughput screening effort of small molecules seeking candidates that enhanced the action of the natural agonist, CCK, thus acting as positive allosteric modulators without exhibiting intrinsic agonist action. Such probes would be expected to act in a temporally finite way to enhance CCK action to induce satiety during and after a meal and potentially even modulate activity at the CCK1R in a high cholesterol environment present in some obese patients. The current work focuses on the best scaffold, representing tetracyclic molecules identified through high throughput screening we previously reported. Extensive characterization of the two top hits from the previous effort demonstrated them to fulfill the desired pharmacologic profile. We undertook analog-by-catalog expansion of this scaffold using 65 commercially available analogs. In this effort, we were able to eliminate an off-target effect observed for this scaffold while retaining its activity as a positive allosteric modulator of CCK1R in both normal and high cholesterol membrane environments. These insights should be useful in the rational medicinal chemical enhancement of this scaffold and in the future development of candidates to advance to pre-clinical proof-of-concept and to clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据